Intravitreal Bevacizumab in Multisystem Inflammatory Syndrome‐Induced Cardiomyopathy

The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request. Video S1: Echocardiography on Day 52 of life: Demonstrates dilated left ventricle with impaired LVEF (39%)—first insult of cardiomyopathy secondary to MIS-N. Video S2: Echocardiography on Day 92 of life: Demonstrates dilated left-sided chamber with poor contractility (LVEF 29%)—after second insult of cardiomyopathy following intravitreal bevacizumab. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.